Home › Trials › NCT06593522

Evaluating AMG 193 for advanced lung cancer with MTAP deletion

A Phase 2 Study Evaluating the Efficacy, Safety, Tolerability, and Pharmacokinetics of Anvumetostat in Subjects With Methylthioadenosine Phosphorylase (MTAP)-Deleted Previously Treated Advanced Non-Small Cell Lung Cancer (NSCLC)

Phase 2 Interventional Amgen · NCT06593522

This study is testing two different doses of a new drug called AMG 193 to see if it can help people with advanced lung cancer that has a specific genetic change and who have already tried other treatments.

Quick facts

PhasePhase 2
Study typeInterventional
Enrollment200 (estimated)
Ages18 Years to 99 Years
SexAll
SponsorAmgen Industry-sponsored
Drugs / interventionsradiation
Locations91 sites (Duarte, California and 90 other locations)
Trial IDNCT06593522 on ClinicalTrials.gov

What this trial studies

This study aims to assess the safety and effectiveness of two different doses of AMG 193 in patients with advanced non-small cell lung cancer (NSCLC) that has a specific genetic deletion (MTAP). Participants must have previously received treatment and experienced disease progression. The efficacy of AMG 193 will be evaluated through a blinded independent review to ensure unbiased results. The study focuses on patients with a confirmed diagnosis of MTAP-deleted NSCLC who meet specific eligibility criteria.

Who should consider this trial

Good fit: Ideal candidates are individuals with metastatic or unresectable locally advanced NSCLC that has a homozygous deletion of the MTAP gene and have progressed after at least one prior systemic therapy.

Not a fit: Patients with tumors that have mutations suitable for targeted therapies other than MTAP deletion may not benefit from this study.

Why it matters

Potential benefit: If successful, this treatment could provide a new therapeutic option for patients with a specific genetic profile of advanced lung cancer.

How similar studies have performed: While there have been studies targeting specific genetic mutations in lung cancer, the approach of using AMG 193 specifically for MTAP-deleted NSCLC is relatively novel.

Eligibility criteria

Show full inclusion / exclusion criteria 
Inclusion Criteria:

* Histologically or cytologically confirmed metastatic or unresectable locally advanced MTAP-deleted (Homozygous deletion of MTAP) NSCLC
* Participants will have received and progressed or experienced disease recurrence on or after receiving at least 1 prior systemic therapy for locally advanced and unresectable or metastatic disease.
* Either an archival tissue sample or an archival block must be available.
* Life expectancy of greater than 3 months, in the opinion of the investigator.
* Participants who have had brain metastases and have been appropriately treated with radiation therapy or surgery ending at least 14 days before study day 1 are eligible.
* Participants with untreated asymptomatic brain metastases smaller or equal to 2 cm in size (per lesion if more than one) and not requiring corticosteroid treatment are eligible.

Exclusion Criteria:

Disease Related

• Tumors harboring the following mutations amenable to targeted therapies: epidermal growth factor receptor (EGFR), ALK receptor tyrosine kinase (ALK), ROS proto-oncogene 1 (ROS1), neurotrophic tyrosine receptor kinase (NTRK), MET proto-oncogene (MET), B-Raf proto-oncogene (BRAF), RET proto-oncogene (RET), Human epidermal growth factor receptor 2 (HER2/ERBB2), KRAS proto-oncogene G12C (KRAS G12C).

Other Medical Conditions

* Major surgery within 28 days of study day 1.
* Untreated symptomatic central nervous system (CNS) metastatic disease regardless of size or asymptomatic brain metastases greater than 2 cm per lesion.

Where this trial is running

Duarte, California and 90 other locations

+41 more sites — see ClinicalTrials.gov for the full list.

Study contacts

How to participate

  1. Review the eligibility criteria above with your treating physician.
  2. Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
  3. Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
View on ClinicalTrials.gov → Find more trials like this →
Conditions MTAP-deleted NSCLCOncologyanvumetostat
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.